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ABSTRAK 
 
Jangkitan kuman disentri adalah penyebab jangkitan silang diarea yang paling umum di 
negara-negara membangun. Setiap tahun, terdapat kira-kira 165 juta kes shigellosis yang 
dilaporkan di seluruh dunia. Penghidratan semula dan penggunaan antibiotik adalah 
rawatan yang biasa untuk shigellosis. Namun demikian, pengedaran dan penggunaan 
antibiotik yang tidak terkawal telah menyebabkan wujudnya strain rintang dadah. Shigella 
telah menunjukkan pelbagai kerintangan terhadap ubat-ubatan yang boleh digunakan 
untuk merawat jangkitannya. Dengan peningkatan kerintangan ubat yang ketara, cara 
terbaik untuk memerangi jangkitan ini ialah dengan mengenalpasti dan membangunkan 
protein immunogenic baru yang boleh digunakan untuk menghasilkan vaksin yang sesuai. 
Dalam kajian ini enam protein immunogenic luar membran telah dikenalpasti 
menggunakan pendekatan immunoformatics sebagai calon vaksin yang berpotensi pada 
masa akan datang. Daripada enam protein ini, dua protein panjang penuh dipilih dan di 
satukan menjadi rekombinan yang ditandai dengan protein His. Protein chimeric 
kemudiannya dihasilkan dengan menggabungkan sebahagian protein daripada kedua-dua 
protein panjang penuh tersebut. Ekspresi protein dilakukan dengan menggunakan sistem 
bakteria BL 21(DE3). Secara keseluruhannya penilaian kawasan pengekodan protein 
dengan kereaktifan imunologi boleh menghasilkan pengenalan antigen tambahan Shigella 
yang akan berguna sebagai vaksin dan reagen baru untuk diagnosis shigellosis. 
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ABSTRACT 
In the developing world, bacillary dysentery is one of the most common communicable 
diarrheal infection. Approximately every year there are approximately 165 million cases 
of shigellosis that is reported worldwide. Treatment of shigellosis include oral rehydration 
and the use of antibiotics. However due to uncontrolled use and distribution of antibiotics, 
has led to the emergence of resistant strains. Shigella is once organism that has shown 
multiple drug resistance (MDR) to most of the drugs that have been used against it. With 
rapid increase in resistant strain the best way to combat this infection is by identifying and 
developing new immunogenic proteins that can be used to develop suitable vaccines. In 
this study, six immunogenic outer membrane proteins that could be used as potential 
vaccine candidates in the future were identified using immunoinformatics approach. From 
these six immunogenic proteins, two full length proteins were selected and expressed as 
recombinant His-tagged proteins. A chimeric protein that was then engineered by 
combining partial fragment of these two full length proteins. The expression of these 
proteins were carried out using BL21 (DE3) bacterial system. Overall, evaluation of these 
regions for encoding proteins with immunological reactivity can lead to the identification 
of additional antigens of Shigella which are useful as new vaccines and reagents for 
specific diagnosis of shigellosis. 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
1. Overview   
Shigella is a gram-negative intracellular pathogenic enterobacteria genus, which is 
responsible for causing bacillary dysentery or shigellosis worldwide. It consists of 4 
species namely Shigella flexneri, S. sonnei, S. dysenteriae and S. boydii. Each of these 
species is composed of different serotypes which can be identified based on the structure 
of their lipopolysaccharide O-antigen. S. flexneri, S. boydii and S. dysenteriae are the 
common causative agents of shigellosis in the developing world whereas S. sonnei is found 
to cause infections in developed countries. Shigella sp. invades and colonizes the colonic 
mucosa leading to its disruption. The bacilli invade the villi of the large intestine, multiply 
and spread laterally to adjacent epithelial cells and also penetrate into the lamina propria 
(Warren, Parish and Schneider, 2006; Banga Singh et al., 2011). 
 Since the pathogen is intracellular it become even more difficult to treat. The symptoms 
associated with shigellosis range from mild self-limited diarrhea to severe dysentery with 
frequent passage of blood and mucus, high fever, abdominal cramps, malaise, chills, 
nausea, vomiting and in rare cases known to cause bacteremia. The diagnosis depends on 
the presence of erythrocytes, polymorphonuclear neutrophils (PMNs) and mucus in the 
patients stool sample (Warren, Parish and Schneider, 2006; Banga Singh et al., 2011; 
Anderson, Sansonetti and Marteyn, 2016).  
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This organism is mostly seen to infect children of age 5 years or younger and is one of the 
third most common bacterial agent responsible for childhood diarrhea. Apart from young 
children this pathogen also targets elderly and immunocompromised patients. Its mode of 
transmission is by fecal-oral route and requires a minimum infectious dose of  <10 to 100 
bacilli to cause the infection, due to its ability to survive gastric acidity better than other 
enterobacteria (Banga Singh et al., 2011). However if immediate action is taken to cure 
the infection with the use of effective antimicrobial agents it may be possible to curtail the 
clinical symptoms and control the spread of the infection. The uncontrolled use of 
antimicrobial agents against Shigella sp. has inadvertently led to the development of 
resistant strains, which hinder appropriate selection of effective antibiotics. The variation 
in antimicrobial resistance from region to region further exacerbates selection of an 
appropriate antibiotic. According to a report by Kotloff et al. (1999), the percentage 
distribution of  Shigella species in develop and developing countries was found to be as 
follows: 
Species Developing countries Developed countries 
S. flexneri 60% 16% 
S. sonnei 15% 77% 
S. boydii 6% 2% 
S. dysenteriae 6% 1% 
 
Outbreak of shigellosis is mainly due to consumption of contaminated water, food, 
overcrowded communities, unhygienic food handlers and houseflies (Kapperud et al., 
1995; Shears, 1996).  
3 
 
 The treatment includes both rehydration and antibiotic therapy. As recommended by 
WHO a 5-day course of antibiotic is effective in treating diarrhea. However Shigella has 
evolved over the years and has become multi-drug resistant. It has shown resistance to 
sulphonamide, tetracycline, chloramphenicol, ampicillin and many more with increase in 
uncontrolled use and distribution of antimicrobial agent’s future control of antimicrobial 
resistance will be very difficult to achieve (Niyogi, 2007). Effective approach against 
shigellosis in developing countries relies on environmental sanitization, personal hygiene 
and  to develop safe and effective vaccines (Niyogi, 2007). 
 Development of vaccine through conventional techniques take decades to develop and 
with an increasing rate of emerging antimicrobial resistant organisms conventional 
methods of vaccine development is not a good idea, but now due to the availability of 
whole genome sequences, the genomic data could be used in silico to help identify and 
screen for potential vaccine candidates. This technique to develop vaccine using in silico 
method is termed as ‘Reverse Vaccinology (Mora et al., 2003; Rappuoli, 2009). To select 
a potential vaccine candidate it is essential to identify the virulent protein that is capable 
to evoke an immune response within the host organism. Some features for an effective 
vaccine candidate protein include: (i) sub-cellular localization; (ii) presence of a signal 
peptide; (iii) transmembrane domain; and (iv) antigenic epitopes. The main strategy 
behind identification of potential vaccine candidates is recognizing the antigenic and 
virulence factor as well as predicting those sequences which are likely to bind MHC class 
I and II proteins within the host. One such example that made use of reverse vaccinology 
was for the development of vaccine against Group B meningococcus (MenB) (Rappuoli, 
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2001, 2009; Mora et al., 2006; Doytchinova and Flower, 2007; Movahedi and Hampson, 
2008; Naz et al., 2015).  
The current study is based on the use of computational pipelines for the identification of 
putative vaccine targets against S. flexneri. Essential proteins were first identified, 
followed by determining which were antigenic. Subsequently the proteins were scanned 
for those epitopes having the ability to bind with both B-cells and T-cells. Identification 
of potential antigens can help in the development of protective immunogens against 
various other pathogens (Naz et al., 2015). Using the identified vaccine candidate, a 
chimeric molecule was designed and its immunogenic response was tested using 
molecular techniques (Figure 1).  
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Fig1. Workflow used in this experiment. 
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1.1  History of Shigella 
The first organism that was identified from the genus Shigella was Shigella dysenteriae 
type 1. This bacterium was named after Kiyoshi Shiga, a Japanese scientist who was the 
first person to identify and examine dysenteric stools of patients and managed to isolate 
the bacteria. After the identification of S. dysenteriae, the next few decades saw the 
identification of other species such as S.  flexneri, S. sonnei and S. boydii that were named 
according to their lead workers (Taneja and Mewara, 2016). 
Modern medical and public health efforts in controlling the global spread of shigellosis 
has not been very successful especially in the developing countries. During the 1970s 
dehydration related with diarrhea could be controlled by giving the patient a strong dose 
of oral rehydration thereby reducing the mortality of the problem. However oral 
rehydration had very little benefits to individuals who were infected with invasive 
bacterial enteropthogens such as Shigella thereby making dysentery a clinical problem in 
developing countries (Kotloff et al., 1999). In Bangladesh between the year 1975 and 1985 
the data collected by diarrheal disease center showed that the deaths attributed to acute or 
chronic dysentery between age groups 1-4 years outnumbered the deaths attributed to 
acute or chromic watery diarrhea by a factor ranging from 2.1 to 7.8 (Bennish and 
Wojtyniak, 1991).  
As time progressed antimicrobial treatments became available that could be used to treat 
shigellosis if diagnosed at an early stage, but due to uncontrolled use and spread of 
antimicrobial agents the organism has developed extraordinary prowess in acquiring 
plasmid-encoded resistance to the antimicrobial drugs that were  considered as the first 
line of therapy.  Few of these first line drugs that were considered to be highly effective 
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against this organism were sulfonamides, tetracycline, ampicillin and trimethoprim-
sulfamethoxazole however these drugs are currently impotent against shigellosis ( Kotloff 
et al., 1999).   
1.2  Classification 
Shigella belongs to the Enterobacteriaceae family and the in species is classified into 
different serotypes based on their biochemical difference and variations in O-antigen. 
There are 4 serogroup A to D, group A (S. dysenteriae) has 17 serotypes, group B (S. 
flexneri) has 14 serotypes, group C (S. sonnei) has a single serotype and group D (S. 
boydii) has 20 serotypes. Each of these serogroup differ in their distributions (Taneja and 
Mewara, 2016). A multi-centric study from six Asian countries showed that 68% of 
isolated species in China, Vietnam, Bangladesh, Pakistan and Indonesia were S. flexneri, 
whereas in Thailand the most common isolated species (84%) was found to be S. sonnei, 
while only 4% of S. dysenteriae isolates are common in southern Asia and sub-Saharan 
Africa.  This heterogeneous distribution of Shigella species and its serogroup indicates 
that a multivalent or a cross-protective vaccines is required to control the burden of 
shigellosis in these developing countries (von Seidlein et al., 2006).  
1.3  An etiology of Shigella  
Shigella is a gram negative, lactose negative, facultative intracellular pathogen that is 
closely related to Escherichia coli (E. coli). This organism is the etiological agent of 
bacillary dysentery or shigellosis.  The chromosomal genes of this organism controls the 
two most studied pathogen associated molecular patterns (PAMPS): the 
lipopolysaccharide (LPS) on the bacterial surface and the peptidoglycan (PGN) between 
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the inner and outer membrane. The virulence is based on the presence of large virulence 
plasmid, that encode a Type III secretion system (T3SS), and a set of secreted protein that 
are the virulence effectors.  
 
Fig 2: Rod shape bacilli of Shigella Spp. (Getty Images, 2017) 
1.4  Epidemiology of Shigella 
Shigella is responsible for causing bacillary dysentery in children below the age of 5 and 
elderly individuals with an immunocompromised immune system. It’s one of the major 
species with high morbidity and mortality rate, nearly 165 million causes of shigellosis 
and about 1 million associated death are reported annually worldwide most of this reports 
come from developing countries such as sub-Saharan Africa and south Asia ( Kotloff et 
al., 1999; Kotloff et al., 2013). Shigella species are endemic in temperate and tropical 
climates (Prevention, 2017).  
Its mode of transmission is mostly through the fecal-oral route and requires a minimum 
dose of less than 10 to 100 bacilli to cause an infection (Banga Singh et al., 2011). The 
impact of Shigella on developing countries is higher compared to developed countries, 
this is mainly because of the poor infrastructure and hygienic conditions. The most 
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common route of transmission in developing countries is through consumption of 
contaminated water, food and unhygienic practices where as in develop countries most 
cases are transmitted by fecal-oral spread from people with symptomatic infection. 
Outbreaks in developed countries are most commonly related with institutions such as day 
care centers, schools etc. (Rabia Agha, MDMarcia B Goldberg, 2017).  
Out of all the four species of Shigella, shigellosis in industrial countries is mostly caused 
by S. sonnei, whereas in developing countries the most common organism responsible for 
shigellosis is S.  flexneri. There have been several reports of outbreaks across many Asian 
countries such as Bangladesh (1972-1978, 2003), Sri Lanka (1976), Maldives (1982), 
Nepal (1984-1985), Chandigarh India (2003). During the 1984 outbreak in West Bengal 
and Tripura approximately 3, 50,000 people were affected with 3500 death giving an 
indication that Shigella has the ability to cause an outbreak involving a large population. 
Multiple Drug resistant S. dysenteriae serotype 1 is the current cause of epidemic 
dysentery faced by developing countries (Taneja and Mewara, 2016).  
1.5  Multiple Drug Resistance (MDR) to Shigella 
Multiple drug resistance (MDR) to Shigella has been reported all over the world including 
countries like USA, China, Iran, Indonesia and many more (Taneja and Mewara, 2016). 
The first drug which was used against Shigella was sulphonamide that was introduced in 
the early 1940’s and was highly sensitive against all Shigella strains. However by the late 
1940’s it became ineffective, thereby using other drugs like tetracycline, chloramphenicol, 
ampicillin, co-trimoxazole, nalidixic acid and fluoroquinolones.  Shigella became resistant 
to tetracycline and chloramphenicol in 1980’s followed by nalidixic acid in 1988 due to 
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the outbreak in Tripura, which made way for fluoroquinolones as the drug of choice, which 
was very effective against MDR Shigella.  
In 1990 ciprofloxacin proved to be effective against shigellosis, yet due to uncontrolled 
used of such fluoroquinolones resulted in the emergences of resistance strains against 
these antibiotics as well. Currently the World Health Organization (WHO) recommends 
ceftriaxone, pivmecillinam and azithromycin as an alternative to fluoroquinolone resistant 
Shigella.  However over the period of nine years (2000-2009) resistance to at least one of 
the third generation cephalosporin’s (ceftriaxone/ cefotaxime) has been noted. First isolate 
showing resistance to ceftriaxone was seen in 2001 followed by an increase in resistant 
strains by 2005 and currently on the rise, thereby making therapeutic treatment a challenge 
(Taneja and Mewara, 2016). 
1.6  Clinical Manifestation 
The clinical manifestation of shigellosis begins with most common symptoms such as 
fever, anorexia and malaise. Initially the diarrhea of the infected patient is watery, but as 
the disease progresses it may contain blood and mucus. Usually the incubation period 
required for the organism to develop the symptoms ranges from one to seven days, with 
an average of three days (Rabia Agha, MDMarcia B Goldberg, 2017). The severity of the 
disease depends on the serogroup of the infecting organism. S. sonnei commonly causes 
mild disease, which is limited to watery diarrhea, while S. dysenteriae or S. flexneri are 
most commonly responsible for bloody diarrhea (Khan, Griffiths and Bennish, 2013). In 
a normal host the disease is generally self-limited, when left untreated will last of less than 
seven days.  
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There is a possibility that during a shigellosis infection there may be rare cases of intestinal 
and systemic complications such as in table 1.1: 
Table1.1: Complications associated with Shigellosis 
Intestinal Complication Systemic Complications 
Proctitis/ rectal prolapse Bacteremia 
Toxic megacolon Metabolic disturbances 
Intestinal obstruction Leukemoid reaction 
Colonic Perforation Neurologic disease 
 Reactive arthritis 
 Hemolytic-uremic syndrome 
 
Few other complications of shigellosis include vaginitis or vulvovaginitis with or without 
diarrhea which occurs in young girls. In very rare cases Shigella may cause Keratitis or 
Conjunctivitis in young children who have recently been exposed to the illness. Shigella 
may also cause acute myocarditis. However these complications differ from species to 
species (Rabia Agha, MDMarcia B Goldberg, 2017).  
1.7  Host and Risk groups 
The primary reservoirs for Shigella are humans and primates. It has been isolated from 
various sources viz.  aquatic bodies (rivers, surface waters), free living amoebae, insects, 
birds and wild animals (Taneja and Mewara, 2016).  
Risk group associated with Shigella are mostly children who are less than five years of 
age. This pathogen can have a serious effect especially on children’s who are 
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malnourished causing further impairment of nutrition, growth retardation and recurrent 
infection. In developed countries the individuals who are most often infected are migrant 
populations, travelers to developing countries, children in day-care facilities, prisoners and 
military personnel, and homosexual men. However no individual is immune to shigellosis 
especially during an epidemic outbreak where all age groups are at the risk of acquiring 
the infection (Taneja and Mewara, 2016). 
1.8  Route of transmission 
In the developing countries, high incident of shigellosis is mainly due to lack of clean 
water, poor hygiene conditions, malnutrition and close personal contact. However the 
most common route of transmission is by fecal oral route. There have been outbreaks that 
have been associated with person to person especially seen in crowded or unhygienic 
environments like prisons and asylums (Taneja and Mewara, 2016). Transmission can also 
be triggered by environmental factors such as rainfall and temperature. It has been seen 
that the organism can express its virulence gene when the temperature shifts from 30oC to 
37oC when left in a medium of moderate osmotic stress with a pH of 7.4 (Dorman and 
Porter, 1998). Outbreaks associated with Shigella can occur round the year but higher 
cases of outbreaks are mostly seen during summer, this may be due hot and dry weather 
possibly due to lack of water thereby limiting hygiene conditions like washing hands. 
Another route of transmission is food, especially foods and beverages that are prepared by 
street-vendors. Thereby making food-handlers as a source of transmission. Areas with 
inadequate facilities for disposal of human faeces can provide a breeding ground for flies 
particularly Musca domestica; the common housefly,  thereby making them a vector for 
transmission (Taneja and Mewara, 2016).  
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1.9  Pathogenesis 
S. flexneri requires less than 100 cells to cause an infection, this is mainly because the 
organism has the ability to survive in the low acidic conditions of the host’s stomach via 
an up-regulation in acid resistant genes. The clinical symptoms of shigellosis is seen when 
the organism successfully destroys the colonic epithelium of the host. To be able to destroy 
the epithelium the organism must first reach the colon, invade, penetrate, replicate within 
the mucosa and spread between the mucosal epithelial cells resulting in a subsequent 
inflammatory response of the host causing the destruction of the colonic epithelium 
(Jennison and Verma, 2004). 
Through the follicular associated epithelium (FAE) which is located above the mucosa-
associated lymph nodes the organism penetrates the epithelial lining. This region consists 
of endocytic M cells (Membranous epithelial cells) which have transcytotic (transcellular 
transport) properties. Many organism including Shigella exploit of this property of the M-
cells and use it as a route for invasion of the impermeable epithelial lining (Jennison and 
Verma, 2004).  
In order for the organism to amplify its penetration into the colonic epithelium, it exploits 
the host’s immune response. The macrophages that are infected by the organism undergo 
apoptosis, releasing large amounts of IL-1 (Interleukin-1), who play an important role in 
inducing inflammatory response. The invasion of the epithelial cells by the organism 
activates the transcription and secretion of IL-8, which is responsible in recruiting 
Polymorphonuclear cells (PMN) to the luminal bacteria in the infected area. This influx 
of PMN disrupts the integrity of the epithelium, allowing the luminal bacteria to cross the 
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submucosa and cause further inflammation and destruction of tissues (Jennison and 
Verma, 2004).  
1.10  Diagnosis, Treatment and Prevention 
Based on typical clinical suspicion like fever, pain, watery or bloody diarrhea in patients 
who are likely to have been exposed to the bacteria makes a doctor suspicious of 
shigellosis. Preliminary test includes checking for the presence of white blood cells and 
red blood cells on direct microscopic examination of the stool sample which is consistent 
with the diagnosis of Shigella. To confirm the diagnosis, stool sample is taken from the 
patients and sent to the laboratory for further test for organism identification; such as stool 
culture, molecular testing and susceptibility testing (Shigella infection - Diagnosis and 
treatment - Mayo Clinic, no date; Rabia Agha, MDMarcia B Goldberg, 2017). 
In a healthy individual Shigella may be treated by giving the patients lots of fluids 
containing salts in order to replace the lost fluids. Antibiotics may be used to shorten the 
duration of infection with the exception if the strain is multiple drug resistant than 
antibiotics should be avoided (Shigella infection - Diagnosis and treatment - Mayo Clinic, 
no date, Shigellosis - Infections - Merck Manuals Consumer Version, no date). 
The best way to avoid the disease is to use precaution methods like: (i) Follow proper 
personal and sanitary hygiene; (ii) infected individuals should not be allowed to prepare 
food for others; and (iii) infected children should not be allowed to interact with other 
healthy children till they are cured (Shigellosis - Infections - Merck Manuals Consumer 
Version, no date). One of the best way to prevent the disease is to design safe and effective 
vaccines that can be used to combat the infection.  
15 
 
1.11 Overview on vaccine design 
The journey of development of vaccines began in 1796 when Edward Jenner created the 
first vaccine to protect human from smallpox. This work became the foundation for the 
design of various vaccines. Vaccines against bacterial infections such as diphtheria, 
tetanus, anthrax, cholera, plague, typhoid, tuberculosis were developed in 19th century  
(Anon., 2011). By the middle of 20th century, vaccine research and development became 
an active area of interest which led to the development of vaccines against viral infections 
like polio, measles, mumps, and rubella (Serruto and Rappuoli, 2006; Movahedi and 
Hampson, 2008; Bambini and Rappuoli, 2009).  
While effective vaccines have been developed with conventional methods (Figure 3) to 
fight against microbial infections, there are still some limitations yet to overcome 
particularly: (i) not all pathogens can be grown in culture (ii) some cell associated 
microorganisms require specific cell cultures for growth (expensive cost) (iii) extensive 
safety procedure for personnel and environment may be required to prevent exposure to 
pathogenic microorganisms (iv) insufficient killing or attenuation may result in the 
introduction of virulent organisms into the final vaccine and inadvertently cause disease 
(v) time consuming (Movahedi and Hampson, 2008; Bambini and Rappuoli, 2009). 
 Therefore, innovative techniques have been devised to design vaccines that are safe, more 
efficacious, and less expensive than traditional vaccines, also there has been an expansion 
in the disease targets, scientists now are not only focusing on developing vaccines for 
infectious diseases but are also focusing on designing vaccine for non-infectious 
conditions like allergies and cancers.  
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Fig 3: Schematic representation of the conventional approach to bacterial vaccine 
development. 
1.12 The in silico Approach 
In silico approach provides computational methods to predict and design new vaccine 
components. Two promising in silico fields that have widely contributed to the 
development of vaccine are bioinformatics and immunoinformatics. Bioinformatics is a 
field of science that represents the convergence of several different disciplines in order to 
organize and store large amounts of biological information which are generated from 
experiments conducted in the field of genetics, molecular biology and biotechnology 
(Soria-Guerra et al., 2015).  
The field of bioinformatics comprises of various studies including proteomics, genomics 
and vaccinomics. The information obtained from these disciplines speed up the 
identification and characterization of new antigens. Over the years, sequencing 
experiments have generated a large amount of data relevant to immunology research. With 
recent advancement in research methodologies, huge amounts of functional, clinical and 
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epidemiologic data are being reported and deposited in various specialist repositories and 
clinical records (Soria-Guerra et al., 2015). Combining this accumulated information 
together can provide insights into the mechanisms of immune function and disease 
pathogenesis. Hence, the need to handle this rapidly growing immunological resource has 
given rise to the field known as immunoinformatics (Tomar and De, 2014; Soria-Guerra 
et al., 2015).  
The main objective of immunoinformatics is to convert large-scale immunological data, 
using a wide variety of computational, mathematical and statistical methods that range 
from text mining, information management, sequence analysis and molecular interactions 
to understand and organize these large scale data to obtain immunologically meaningful 
interpretations. Also attempts are being made for the extraction of interesting and complex 
patterns from non-structured text documents in the immunological domain, including 
categorization of allergen cross-reactivity information, identification of cancer-associated 
gene variants, and the classification of immune epitopes (De and Tomar, 2014). The tools 
used in this field are based on statistical and machine learning system and are used for 
studies in modeling molecular interaction. They also play a role in defining new 
hypothesis related to understand the immune system mechanism (Backert and 
Kohlbacher, 2015). 
Advanced knowledge in the field of infectious disease such as pathogenesis, virulence 
factor and the host immune response has assisted us in overtaking the traditional method 
of vaccine development (Movahedi and Hampson, 2008). The advancement in the field 
has led to the development of second generation vaccines. Later, with the integration of 
the development in bioinformatics tools along with the advancement in recombinant DNA 
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technologies (rDNA), such approach provides another series of advancement in the field 
of vaccine development resulting in the rises of third generation vaccines known as 
Reverse Vaccinology. The Reverse Vaccinology approach coined by Rino Rappuoli was 
first developed to develop potential pathogenic microbial vaccine based on genomic data 
(Movahedi and Hampson, 2008; Bambini and Rappuoli, 2009). It starts from the whole 
genomic sequence and through computer analysis to predict those proteins that are most 
likely to be effective vaccine components. This approach is widely applicable as there are 
many genome sequences available publicly. It was firstly applied for the development of 
vaccines against serogroup B Neisseria meningitids (Rappuoli, 2000).  
In 2008, a cutting-edge reverse vaccinology program known as Vaxign was successfully 
developed. Typically, the program comprises of a comprehensive pipeline that using 
bioinformatic technology to find potential genes from the genomes for developing 
vaccines. The program has also been developed to predict possible antibody targets based 
on various criteria by utilizing microbial genomic and protein groupings as data 
information (Xiang and He, 2009). The major predicted features include subcellular 
location of proteins, transmembrane domain, adhesion probability, sequence similarity to 
host proteome and MHC class I and II epitope binding (Xiang and He, 2009). Out of these 
features, subcellular localization is considered to be as one of the main criterion for target 
prediction (He, Xiang and Mobley, 2010).  This program is a part of web based system 
called Vaccine Investigation and Online Information Network (VIOLIN, 
http://www.violinet.org). Vaxign has widely been used for the prediction of vaccine 
targets against bacteria like Brucella spp., Neisseria meningitides and Mycobacterium 
tuberculosis since it was developed (Xiang and He, 2009; He, Xiang and Mobley, 2010). 
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1.13 From genomics to epitope prediction 
High throughput human leukocyte antigen (HLA) binding assay and Next Generation 
Sequencing  (NGS) has led to major progress in this field exclusively on epitope prediction 
tools development (Backert and Kohlbacher, 2015). Basically, the immunogenicity of an 
antigen is associated with its ability to interface with the humoral (B-cell) and cellular (T-
cell) immune systems. An immunogen construct containing both B- and T-cell epitopes is 
crucial to effectively induce strong immune responses when in contact with host immune 
system (He et al., 2010; Moise et al., 2011). The progression from genomics to epitope 
prediction has led us toward the evolution of designing epitope based vaccines.  
Epitopes hold huge potential for vaccine design, disease prevention, diagnosis and 
treatment and are therefore of particular interest both clinical and basic biomedical 
researchers (Soria-Guerra et al., 2015). With recombinant DNA technologies (rDNA) it 
is possible to isolate specific epitopes which replace the whole pathogen in a vaccine, also 
can design vaccines that consist of chimeric proteins (multi-epitope vaccine) in order to 
enhance a strong immune response. These features offer the possibility of designing multi-
target highly efficient vaccine, but it is not an easy process as proper identification of the 
immunogenic peptide is necessary in order to elicit an immune response (Soria-Guerra et 
al., 2015). A good epitope-based vaccine should possess two features: - (i) it should be 
known if the selected epitope for the vaccine is conserved across different stages of the 
pathogen and its variant; (ii) the desired immune response should also be taken into 
consideration. All the information mentioned above for the design of epitope-based 
vaccine can now be performed using immunoinformatic approach (Figure 4). 
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Fig 4: Schematic workflow to identify epitope for vaccine development. 
1.14 B-cell epitope prediction and tools 
Identification of B-cell epitopes plays an important role in development of epitope-based 
vaccines, therapeutic antibodies, and diagnostic tools. Surface immunoglobulins of B-
cells and antibodies recognize the B-cell epitope of an antigen in its native conformation. 
There are two types of B-cell epitope which are known as continuous (linear/sequential) 
or discontinuous (conformational). In general, B-cell epitopes bind to B-cell receptors 
(BCR) and the binding site of these receptors (BCR) are primarily hydrophobic, consisting 
of 6 hyper variable loops of varied lengths and amino acid composition (Tong and Ren, 
2009; Tomar and De, 2014; Soria-Guerra et al., 2015).  
Prediction of B-cell epitopes is primarily based on its amino acid properties such as 
hydrophilicity, the charged exposed surface area and secondary structure. It is estimated 
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that about 85% of documented B-cell epitopes could be considered to be continuous in 
sequence, but it should be noted that not all residues within an epitope are functionally 
essential for binding, and this binding efficacy depends on the amino acid sequence such 
that, if a single amino acid is substituted or eliminated then the binding efficacy is reduced 
(Kringelum et al., 2013; Tomar and De, 2014; Backert and Kohlbacher, 2015; Soria-
Guerra et al., 2015).  
In contrast, in discontinuous B-cell epitopes the discontinuity is because distant residues 
are brought into spatial proximity by protein folding. These complex structures of folded 
proteins lead to spatial proximity of amino acids that can be remote in the antigen 
sequence. Prediction of discontinuous B-cell epitope is difficult because two reasons (i) 
not many prediction software are available for discontinuous B-cell epitopes and (ii) 
because classic machine learning based system require a continuous sequenced data.  
(Saha, Bhasin and Raghava, 2005; Tong and Ren, 2009; Tomar and De, 2010; Backert 
and Kohlbacher, 2015). 
Selected specific web-based servers available for the prediction of continuous or 
discontinuous B-cell epitopes are listed in Table 1.2. These integrative B-cell prediction 
tools shed light on the identification of immunogenic B-cell epitopes which are potentially 
to trigger antibody response in the host immune system (Soria-Guerra et al., 2015). 
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Table 1.2: List of some servers used for the prediction of B cell epitopes 
Server 
name 
Type of 
prediction 
Link Reference 
BcPred 
Continuous B 
cell epitopes 
http://ailab.ist.psu.edu/bcpreds/pre
dict.html 
(Chen et al., 2007; 
El-Manzalawy, 
Dobbs and 
Honavar, 2008a, 
2008b) 
BepiPred 
Continuous B 
cell epitopes 
http://www.cbs.dtu.dk/services/Be
piPred/ 
(Jespersen et al., 
2017) 
ABCPred 
Continuous B 
cell epitopes 
http://www.imtech.res.in/raghava/
abcpred/  
(Saha and G P S 
Raghava, 2006) 
 
BcePred 
Continuous B 
cell epitopes 
http://www.imtech.res.in/raghava/
bcepred/ 
 
(Saha and Raghava, 
2004) 
EPCES 
Discontinuous 
B cell epitope 
http://sysbio.unl.edu/EPCES/ 
 
(Liang et al., 2007) 
 
DiscoTope 
Discontinuous 
B cell epitope 
http://www.cbs.dtu.dk/services/Di
scoTope/  
(Kringelum et al., 
2012) 
BEPro 
(PEPITO) 
Discontinuous 
B cell epitope 
http://pepito.proteomics.ics.uci.ed
u/ 
(Sweredoski and 
Baldi, 2008) 
Ellipro 
Discontinuous 
B cell epitope 
http://tools.iedb.org/ellipro/ 
 
(Ponomarenko et 
al., 2008) 
 
1.15 T-cell epitope prediction and tools 
T-cell epitopes are parts of intracellular processing antigens that are presented to T 
lymphocytes in association with molecules of the major histocompatibility complex 
(MHC). Antigenic peptides bound with MHC are presented to T-cell for immunity 
stimulation. Therefore identification of these MHC binding peptides is a central part of 
any algorithm that is used to predict T- cell epitopes (Tomar and De, 2014). T-cell epitopes 
are bound in a linear form to MHCs, the interface between ligands and T-cells can be 
modeled with accuracy. These epitopes are linked together into the binding grove of MHC 
class I and class II molecules, through interaction between their R group side chain and 
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pockets located on the floor of the MHC (Falk et al., 1991; Rötzschke et al., 1991; 
Zinkernagel and Doherty, 1997; Soria-Guerra et al., 2015). Hence based on this 
knowledge large number of computational tools have been established and used for 
identifying putative T-cell epitopes and MHC binding peptides (Table 1.3). The 
identification of these putative T-cell epitopes and MHC binding peptides is based on 
various algorithms such as artificial neural network (ANN), protein threading and docking 
techniques, hidden Markov model (HMM) and decision tree (Tong and Ren, 2009). 
Among all the MHC I and MHC II binding predictor software’s, MHC class I predicators 
have displayed to be more efficient in their prediction with an estimated accuracy of 90-
95 %.  Among all the available servers for MHC alleles, RANKPEP is one server which 
makes use of Position Specific Scoring Matrices (PSSMs) to predict peptide binders to 
MHC I and MHC II molecules from protein sequences. It is a friendly platform which 
offers a wide range of allelic coverage to MHC I and MHC II alleles for human and mouse. 
The algorithm used by this database is written in Python, and it sorts and stores all protein 
segments with the length of the PSSM width. The scoring starts at the beginning of each 
sequence and the PSSM is slid over the sequence one residue at a time until reaching the 
end of the sequence. Furthermore a threshold value is set in order to narrow down the 
potential binders from the list of ranked peptides; a binding threshold is defined as a score 
value that includes 90% of the peptides within the PSSM. This binding threshold value is 
built into each matrix, delineating the range of putative binders among the top scoring 
peptides (Reche, Glutting and Reinherz, 2002; Reche et al., 2004; Reche and Reinherz, 
2007).  
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Kernel–based Inter–allele peptide binding prediction system (KISS), predicts if a 9-mer 
peptide will bind to a MHC I molecule of 64 alleles using a support vector machine (SVM) 
multitask kernel to leverage the available training information across the alleles, which 
improves it accuracy especially for the alleles with few known epitopes. The predictor is 
trained on databases which contain known epitopes from SYFPEITHI, MHCBN and 
IEDB databases (El-Manzalawy, Dobbs and Honavar, 2008b). There are many servers 
available for the identification of MHC I binding predictors, the most complete server in 
terms of allelic coverage and identification of alleles were as mentioned above. These 
servers can also identify alleles in other organism besides humans.  
Though MHC class I prediction seems to have achieved a good success, it’s not the same 
for MHC class II. MHC Class II prediction has achieved a very limited success in 
predicting the potential binding epitopes. This is mainly because the predicting accuracy 
is low. There are several factors which is the reason for low accuracy, such as insufficient 
or low quality training data, difficulty in identifying 9-mer binding cores within longer 
peptides used for training and lack of consideration of the influence of flanking residues 
and the relative permissiveness of the binding groove of MHC II molecules which limit 
the binding stringency. For instance, Propred is a server used for the prediction of MHC 
Class II binding regions present in an antigen sequence using quantitative matrices. The 
server implement matrix based prediction algorithm, employing amino-acid/position 
coefficient table deduced from literature. This server assists in locating promiscuous 
binding regions that are useful in selecting vaccine candidates that can bind to 51 HLA-
DR alleles (Sturniolo et al., 1999; Singh and Raghava, 2002). 
 
